UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Royalty Pharma plc (NASDAQ:RPRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 11.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,621,886 shares of the biopharmaceutical company's stock after selling 350,315 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.45% of Royalty Pharma worth $66,884,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Allworth Financial LP raised its holdings in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co raised its holdings in shares of Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 997 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 376 shares in the last quarter. Finally, Rakuten Securities Inc. raised its holdings in shares of Royalty Pharma by 160.5% in the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 1,003 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Morgan Stanley assumed coverage on Royalty Pharma in a report on Friday, May 16th. They issued an "overweight" rating and a $51.00 price objective for the company. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday, May 20th. Finally, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Royalty Pharma presently has an average rating of "Moderate Buy" and an average target price of $42.50.

Royalty Pharma Stock Up 0.7%

Shares of Royalty Pharma stock traded up $0.24 on Tuesday, reaching $32.69. The stock had a trading volume of 2,681,613 shares, compared to its average volume of 3,473,798. The company has a 50 day moving average price of $32.36 and a 200 day moving average price of $30.28. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.32. The stock has a market capitalization of $18.84 billion, a P/E ratio of 22.54, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The firm had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. As a group, equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.69%. Royalty Pharma's payout ratio is 47.57%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.